Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HRTX Heron Therapeutics	$1.33 -1.5%	$1.93	$1.04 ▼ $2.68	$206.94M	1.15	2.12 million shs	1.78 million shs
MDWD MediWound	$18.10 -2.5%	$19.62	$14.14 ▼ $22.50	$200.70M	0.21	68,494 shs	117,753 shs
PDSB PDS Biotechnology	$1.19 -0.8%	$1.32	$0.85 ▼ $4.29	$55.96M	0.95	344,455 shs	339,454 shs
VTYX Ventyx Biosciences	$2.83 -5.7%	$2.61	$0.78 ▼ $3.39	$213.93M	0.97	889,970 shs	704,055 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HRTX Heron Therapeutics	-1.48%	+0.76%	-34.16%	-32.49%	-28.49%
MDWD MediWound	-2.53%	-2.84%	-9.50%	-11.62%	+3.61%
PDSB PDS Biotechnology	-0.83%	+7.21%	-1.65%	-16.20%	-60.60%
VTYX Ventyx Biosciences	-5.67%	+0.71%	-9.58%	+102.14%	+48.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HRTX Heron Therapeutics	4.036 of 5 stars	3.2	1.0	4.2	2.6	3.3	0.6
MDWD MediWound	1.5648 of 5 stars	3.5	1.0	0.0	1.1	0.8	0.6
PDSB PDS Biotechnology	2.0985 of 5 stars	3.7	3.0	0.0	2.6	0.0	0.0
VTYX Ventyx Biosciences	2.7664 of 5 stars	3.3	3.0	0.0	2.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HRTX Heron Therapeutics	2.33	Hold	$4.50	238.35% Upside
MDWD MediWound	3.00	Buy	$32.25	78.18% Upside
PDSB PDS Biotechnology	3.33	Buy	$9.00	656.30% Upside
VTYX Ventyx Biosciences	2.50	Moderate Buy	$7.50	165.02% Upside

Current Analyst Ratings Breakdown

Latest PDSB, HRTX, MDWD, and VTYX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/8/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
7/1/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/11/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HRTX Heron Therapeutics	$144.29M	1.41	N/A	N/A	($0.18) per share	-7.39
MDWD MediWound	$20.22M	9.68	N/A	N/A	$2.89 per share	6.26
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	$0.34 per share	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	$2.94 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HRTX Heron Therapeutics	-$13.58M	-$0.02	N/A	N/A	N/A	-0.62%	N/A	-0.40%	N/A
MDWD MediWound	-$30.22M	-$2.09	N/A	N/A	N/A	-142.18%	-87.63%	-38.99%	N/A
PDSB PDS Biotechnology	-$37.61M	-$0.94	N/A	N/A	N/A	N/A	-184.56%	-79.00%	N/A
VTYX Ventyx Biosciences	-$135.12M	-$1.68	N/A	N/A	N/A	N/A	-48.89%	-44.87%	N/A

Latest PDSB, HRTX, MDWD, and VTYX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	MDWD MediWound	-$0.55	-$1.23	-$0.68	-$1.23	$5.68 million	$5.71 million
8/13/2025	Q2 2025	PDSB PDS Biotechnology	-$0.24	-$0.21	+$0.03	-$0.21	N/A	N/A
8/8/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	-$0.02	-$0.01	-$0.02	$38.08 million	$37.20 million
8/7/2025	Q2 2025	VTYX Ventyx Biosciences	-$0.45	-$0.38	+$0.07	-$0.38	N/A	N/A
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HRTX Heron Therapeutics	N/A	0.82	1.76
MDWD MediWound	N/A	2.15	1.99
PDSB PDS Biotechnology	0.81	2.92	2.33
VTYX Ventyx Biosciences	N/A	19.12	19.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HRTX Heron Therapeutics	80.01%
MDWD MediWound	46.83%
PDSB PDS Biotechnology	26.84%
VTYX Ventyx Biosciences	97.88%

Insider Ownership

Company	Insider Ownership
HRTX Heron Therapeutics	5.86%
MDWD MediWound	9.20%
PDSB PDS Biotechnology	9.20%
VTYX Ventyx Biosciences	14.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HRTX Heron Therapeutics	300	153.29 million	144.31 million	Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable
PDSB PDS Biotechnology	20	46.63 million	41.51 million	Optionable
VTYX Ventyx Biosciences	30	71.31 million	60.98 million	Optionable

PDSB, HRTX, MDWD, and VTYX Headlines

Recent News About These Companies

Ventyx Biosciences Reports Decreased Losses in 2025

August 15 at 3:30 AM | msn.com

3 Best Stocks to Buy Now, 8/11/2025, According to Top Analysts

August 11, 2025 | msn.com

Ventyx Biosciences (NASDAQ:VTYX) Rating Increased to Hold at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Ventyx Biosciences (NASDAQ:VTYX) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

August 10, 2025 | marketbeat.com

Wall Street Zen Upgrades Ventyx Biosciences (NASDAQ:VTYX) to "Hold"

August 10, 2025 | marketbeat.com

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

August 9, 2025 | finance.yahoo.com

Ventyx (VTYX) Q2 Net Loss Drops 16%

August 9, 2025 | theglobeandmail.com

Ventyx Biosciences (VTYX) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

Short Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Expands By 69,900.0%

August 2, 2025 | marketbeat.com

Monaco Asset Management SAM Has $1.31 Million Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

July 30, 2025 | marketbeat.com

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

July 22, 2025 | uk.finance.yahoo.com

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It ... - Nasdaq

July 11, 2025 | nasdaq.com

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?

July 10, 2025 | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)

June 24, 2025 | theglobeandmail.com

VTYX - Ventyx Biosciences Inc News - Morningstar

June 24, 2025 | morningstar.comM

VTYX - Ventyx Biosciences Inc Financials - Morningstar

June 24, 2025 | morningstar.comM

Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m

June 17, 2025 | finance.yahoo.com

Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives

June 17, 2025 | marketwatch.com

Ventyx says Parkinson’s disease drug hit main goal in small mid-stage trial

June 17, 2025 | msn.com

Ventyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial Results

June 17, 2025 | msn.com

Ventyx Biosciences stock trades flat despite positive parkinson’s drug trial data

June 17, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB, HRTX, MDWD, and VTYX Company Descriptions

Heron Therapeutics NASDAQ:HRTX

$1.33 -0.02 (-1.48%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.36 +0.03 (+2.63%)

As of 08/15/2025 07:14 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

MediWound NASDAQ:MDWD

$18.10 -0.47 (-2.53%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$18.10 0.00 (0.00%)

As of 08/15/2025 04:10 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

PDS Biotechnology NASDAQ:PDSB

$1.19 -0.01 (-0.83%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.22 +0.03 (+2.52%)

As of 08/15/2025 07:53 PM Eastern

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Ventyx Biosciences NASDAQ:VTYX

$2.83 -0.17 (-5.67%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.91 +0.08 (+2.83%)

As of 08/15/2025 07:54 PM Eastern

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time